Determination of HER2-low status in tumors of patients with unresectable and/or metastatic breast cancer in DESTINY-Breast04

被引：5
|
作者：
Prat, Aleix
Modi, Shanu
Tsurutani, Junji
Cameron, David
Harbeck, Nadia
Garrido, Charo
Karnoub, Maha
Hsu, Ching
Feng, Wenquin
Yung, Lotus
Wang, Yibin
Gambhire, Dhiraj
Ford, Shirin K.
Vitazka, Patrik
Ueno, Naoto T.
机构：
来源：
CANCER RESEARCH | 2023年 / 83卷 / 05期
关键词：
D O I：
10.1158/1538-7445.SABCS22-HER2-18
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
HER2-18
引用
收藏
页数：3
相关论文
共 50 条
  • [31] Clinicopathological features and prognosis of patients with HER2-low breast cancer
    Xin Yang
    Yao Li
    Xu lu
    Xiaotian Ren
    Bin Hua
    BMC Cancer, 23 (1)
  • [32] Subgroup analysis of patients (pts) with HER2-low metastatic breast cancer (mBC) with brain metastases (BMs) at baseline from DESTINY-Breast04, a randomized phase III study of trastuzumab deruxtecan (T-DXd) vs treatment of physician's choice (TPC)
    Tsurutani, J.
    Jacot, W.
    Yamashita, T.
    Riaz, F.
    Yerushalmi, R.
    Im, S-A.
    Niikura, N.
    Halser-Strub, U.
    Cortes, J.
    Wennstig, A-K.
    Chae, Y.
    Wang, X.
    Li, W.
    Simon, H.
    Masci, G.
    Tamburini, E.
    Aguilar, C. Orbegoso
    Tecson, K.
    Yung, L.
    Modi, S.
    ANNALS OF ONCOLOGY, 2023, 34 : S342 - S343
  • [33] Safety and Efficacy of Trastuzumab Deruxtecan for Metastatic HER2+and HER2-low Breast Cancer
    Qureshi, Zaheer
    Altaf, Faryal
    Jamil, Abdur
    Siddique, Rimsha
    Fatima, Eeshal
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2024, 47 (11): : 535 - 541
  • [34] Trastuzumab Deruxtecan in HER2-Low Breast Cancer
    Carroll, Hailey K.
    Higgins, Michaela J.
    O'Reilly, Seamus
    NEW ENGLAND JOURNAL OF MEDICINE, 2022, 387 (12): : 1144 - 1144
  • [35] Genomic Alterations of Tumors in HER2-Low Breast Cancers
    Tsai, Yi-Fang
    Huang, Chi-Cheng
    Hsu, Chih-Yi
    Feng, Chin-Jung
    Lin, Yen-Shu
    Chao, Ta-Chung
    Lai, Jiun-, I
    Lien, Pei-Ju
    Liu, Chun-Yu
    Chiu, Jen-Hwey
    Tseng, Ling-Ming
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2024, 25 (02)
  • [36] Clinicopathological features and prognosis of patients with HER2-low breast cancer
    Yang, Xin
    Li, Yao
    Lu, Xu
    Ren, Xiaotian
    Hua, Bin
    BMC CANCER, 2023, 23 (01)
  • [37] Characterization of Circulating Tumor Cell-HER2 Status in Patients with HER2-Low Invasive Breast Cancer
    Chen, Jennifer H.
    Meas, Salyna
    Sarli, Vanessa N.
    Koupaei, Negar
    Upshaw, Joshua
    Lucci, Anthony, Jr.
    JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS, 2024, 239 (05) : S49 - S49
  • [38] The effect of eribulin treatment for patients with HER2-low breast cancer
    Goto, Wataru
    Henmi, Saeko
    Nishikawa, Mariko
    Kouchi, Asuka
    Kouhashi, Rika
    Yabumoto, Akimichi
    Takada, Koji
    Asano, Yuka
    Tauchi, Yukie
    Ogisawa, Kana
    Morisaki, Tamami
    Kashiwagi, Shinichiro
    CANCER RESEARCH, 2024, 84 (09)
  • [39] Biology and Treatment of HER2-Low Breast Cancer
    Nicolo, Eleonora
    Tarantino, Paolo
    Curigliano, Giuseppe
    HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 2023, 37 (01) : 117 - 132
  • [40] Intra-patient and inter-metastasis heterogeneity of HER2-low status in metastatic breast cancer
    Geukens, Tatjana
    De Schepper, Maxim
    Richard, Francois
    Maetens, Marion
    Van Baelen, Karen
    Mahdami, Amena
    Nguyen, Ha-Linh
    Isnaldi, Edoardo
    Leduc, Sophia
    Pabba, Anirudh
    Zels, Gitte
    Mertens, Freya
    Borght, Sara Vander
    Smeets, Ann
    Nevelsteen, Ines
    Punie, Kevin
    Neven, Patrick
    Wildiers, Hans
    van den Bogaert, Wouter
    Floris, Giuseppe
    Desmedt, Christine
    EUROPEAN JOURNAL OF CANCER, 2023, 188 : 152 - 160
12345